Ongoing Clinical Trials of the Pleiotropic Effects of Statins

Background The multiple effects (ie, pleiotropic effects of statins) have received increasing recognition and may have clinical applicability across a broad range of cardiovascular and noncardiovascular conditions. Objective To determine the relevance and significance of ongoing clinical trials of the pleiotropic effects of statins, focusing on nonlipid effects. Method Ongoing trials were identified through personal communication, reports presented at scientific meetings (2000–2004), and queries made to AstraZeneca, Bristol-Myers Squibb Co, Merck & Co, Novartis, and Pfizer, manufacturers of the currently marketed statins. Published trials and other source material were identified through electronic searches on MEDLINE (1990–2003), abstract books, and references identified from bibliographies of pertinent articles. Eligible studies were the clinical trials of statins currently under way in which primary or secondary outcomes included the statins' nonlipid (ie, pleiotropic) effect(s). Data were extracted and trial quality was assessed by the authors. Results Of the 22 ongoing trials of the nonlipid effects of statins identified, 10 assessed inflammatory markers and plaque stabilization, 4 assessed oxidized low density lipoprotein/vascular oxidant stress, 3 assessed end-stage renal disease, 3 assessed fibrinogen/viscosity, 2 assessed endothelial function, 2 assessed acute coronary syndrome, 2 assessed aortic stenosis progression, and 1 each assessed hypertension, osteoporosis, ischemic burden, Alzheimer's disease, multiple sclerosis, and stroke (outcomes often overlapped). Conclusion Given the excellent safety and tolerability of statins as a class, full exploration of their pleiotropic effects has the potential to provide additional benefits to many patients.

• Publication year

  2005

• Venue

  Vascular Health and Risk Management

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/VHRM.1.1.29.58937PMID 17319096PMCID 1993933
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A position paper

  2007cited by this paper
• Juvenile recurrent respiratory papillomatosis: Still a mystery disease with difficult management

  2007cited by this paper
• Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study

  2004cited by this paper
• High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

  2004cited by this paper
• High-dose statins in acute coronary syndromes: not just lipid levels.

  2004cited by this paper
• Hyperlipidaemia and aortic valve disease

  2004cited by this paper
• Therapy-refractory systemic juvenile idiopathic arthritis successfully treated with statins.

  2004cited by this paper
• Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women.

  2004cited by this paper
• Effects of HMG-CoA Reductase Inhibitors on Endothelial Function: Role of Microdomains and Oxidative Stress

  2004cited by this paper
• Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

  2004cited by this paper
• Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.

  2004cited by this paper
• Oral simvastatin treatment in relapsing-remitting multiple sclerosis.

  2004cited by this paper
• Antioxidant effects of statins.

  2004cited by this paper
• The cardioprotective effects of statins

  2004cited by this paper
• Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

  2004cited by this paper
• Emphasis on pleiotropic effects, a new paradigm shift?

  2004cited by this paper
• Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme™

  2004cited by this paper
• Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

  2004cited by this paper
• Association of dyslipidemia and effects of statins on nonmacrovascular diseases.

  2004cited by this paper
• The antioxidant effects of statins

  2004cited by this paper
• The cardioprotective effects of statins

  2004cited by this paper
• Anti-inflammatory Effects of Statins in Patients with Aortic Stenosis

  2003cited by this paper
• Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways

  2003cited by this paper
• Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

  2003cited by this paper
• Blood Pressure and Lipid Lowering in the Prevention of Stroke: A Note to Neurologists

  2003cited by this paper
• High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study

  2003cited by this paper
• Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.

  2003cited by this paper
• Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

  2003cited by this paper
• Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure.

  2003cited by this paper
• Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.

  2003cited by this paper
• Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions

  2003cited by this paper
• [Ongoing trials and future prospects].

  2003cited by this paper
• Therapy with statins in patients with refractory rheumatic diseases: a preliminary study

  2003cited by this paper
• Suppression of the Functionally Coupled Cyclooxygenase-2/Prostaglandin E Synthase as a Basis of Simvastatin-Dependent Plaque Stabilization in Humans

  2003cited by this paper
• Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

  2003cited by this paper
• Hyperglycaemia and renal ischaemia-reperfusion injury.

  2003cited by this paper
• Study of Heart and Renal Protection (SHARP).

  2003cited by this paper
• Modulation of Aspirin-Insensitive Eicosanoid Biosynthesis by 6-Methylprednisolone in Unstable Angina

  2003cited by this paper
• Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.

  2002cited by this paper
• Pleiotropic Effects of Statins: Lipid Reduction and Beyond

  2002cited by this paper
• HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.

  2002cited by this paper
• Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain.

  2002cited by this paper
• Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond.

  2002cited by this paper
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

  2002cited by this paper
• Pravastatin promotes coronary collateral circulation in patients with coronary artery disease

  2002cited by this paper
• Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community.

  2002cited by this paper
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events*

  2002cited by this paper
• The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

  2002cited by this paper
• Atorvastatin and Thrombogenicity of the Carotid Atherosclerotic Plaque: the ATROCAP Study

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin.

  2002cited by this paper
• Association of Pravastatin and Left Ventricular Mass in Hypercholesterolemic Patients: Role of 8-Iso-Prostaglandin F2&agr; Formation

  2002cited by this paper
• Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F2-Isoprostane Formation in Hypercholesterolemic Subjects: No Further Effect of Vitamin E

  2002cited by this paper
• Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention

  2002cited by this paper
• Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis.

  2002cited by this paper
• Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.

  2002cited by this paper
• Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Oxidized LDL in Carotid Plaques and Plasma Associates With Plaque Instability

  2002cited by this paper
• Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Isoprenoids as mediators of the biological effects of statins.

  2002cited by this paper
• Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years’ Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging

  2002cited by this paper
• Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo

  2001cited by this paper
• Circulating Cell Adhesion Molecules and Death in Patients With Coronary Artery Disease

  2001cited by this paper
• Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease

  2001cited by this paper
• Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels

  2001cited by this paper
• Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific Aortic Stenosis

  2001cited by this paper
• Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients

  2001cited by this paper
• Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

  2001cited by this paper
• Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

  2001cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

  2001cited by this paper
• Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

  2001cited by this paper
• Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization

  2001cited by this paper
• Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions: A Longitudinal Study by High-Resolution, Noninvasive Magnetic Resonance Imaging

  2001cited by this paper
• [Statins and the risk of dementia].

  2001cited by this paper
• Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

  2001cited by this paper
• Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation

  2001cited by this paper
• Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes

  2001cited by this paper
• Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

  2001cited by this paper
• The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.

  2001cited by this paper
• [HMG-CoA reductase].

  2001cited by this paper
• The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.

  2001cited by this paper
• Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.

  2001cited by this paper
• The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia - The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

  2001cited by this paper
• Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10

  2001cited by this paper
• Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

  2000cited by this paper
• Transthoracic stress echocardiography with transesophageal atrial pacing for bedside evaluation of inducible myocardial ischemia in patients with new-onset chest pain.

  2000cited by this paper
• Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.

  2000cited by this paper
• Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes.

  2000cited by this paper
• Fluvastatin Reduces Soluble P-Selectin and ICAM-1 Levels in Hypercholesterolemic Patients: Role of Nitric Oxide

  2000cited by this paper
• HMG-CoA reductase inhibitors and the risk of fractures.

  2000cited by this paper
• Oral statins and increased bone-mineral density in postmenopausal women.

  2000cited by this paper
• Statins and the risk of dementia.

  2000cited by this paper
• Rationale for a postintervention continuum of care: insights from intravascular ultrasound.

  2000cited by this paper
• Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia.

  2000cited by this paper
• C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

  2000cited by this paper
• Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined.

  2000cited by this paper
• HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients.

  2000cited by this paper
• Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women.

  2000cited by this paper

• Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease

  2023cites this paper
• Phosphatidylserine-containing liposomes: Therapeutic potentials against hypercholesterolemia and atherosclerosis.

  2021cites this paper
• Pleiotropic effects of statins on brain cells.

  2020cites this paper
• Novel therapeutic strategies for Alzheimer’s disease targeting brain cholesterol homeostasis

  2020cites this paper
• Pleiotropic effects of statins: a focus on cancer.

  2020cites this paper
• Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications

  2018cites this paper
• Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study

  2017cites this paper
• PRODUCTION OF LOVASTATIN FROM FUNGAL SOURCES AND ITS MEDICAL APPLICATIONS

  2017cites this paper
• Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy: A Randomized Placebo-controlled Trial.

  2015cites this paper
• Cardiovascular comorbidity in chronic obstructive pulmonary disease: Biomarkers, vascular function and effects of statin treatment

  2015cites this paper
• Preoperative use of statins does not improve outcomes and development of acute renal failure after cardiac surgery. A propensity score analysis of ARIAM-Andalucía database.

  2015cites this paper
• Reply to Letter: "Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy: A Randomized Placebo-controlled Trial".

  2015cites this paper
• The Effects of Atorvastatin and Methotrexate on Freund's Adjuvant–induced Arthritis in Rats

  2015cites this paper
• Osteoporosis in the at‐risk asthmatic

  2014cites this paper
• Simvastatin mitigates functional and structural impairment of lung and right ventricle in a rat model of cigarette smoke-induced COPD.

  2014cites this paper
• The extra-pulmonary effects of chronic obstructive pulmonary disease (COPD)

  2014cites this paper
• Simvastatin: Biological Production, Therapeutic Applications and Proposed Alternative Hypothesis for Biosynthesis

  2014cites this paper
• Do statins have a role in reduction/prevention of post-PCI restenosis?

  2013cites this paper
• Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia.

  2013cites this paper
• Moiety-Linkage Map Reveals Selective Nonbisphosphonate Inhibitors of Human Geranylgeranyl Diphosphate Synthase

  2013cites this paper
• Alternate-day dosing with statins.

  2013cites this paper
• Clinical case: treatment of severe bronchial asthma patients with neutrophilic inflammation type

  2013cites this paper
• Patogenetyczne uzasadnienie stosowania statyn w profilaktyce udaru niedokrwiennego mózgu w świetle zapalnej teorii rozwoju miażdżycy

  2012cites this paper
• Expanding the pleiotropic effects of statins: attenuation of air pollution-induced inflammatory response.

  2012cites this paper
• Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD)

  2012cites this paper
• Pravastatin attenuates noise-induced cochlear injury in mice.

  2012cites this paper
• [Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis].

  2012cites this paper
• Statin Use and the Risk of Age Related Macular Degeneration in a Large Health Organization in Israel

  2011cites this paper
• Beneficial Pleiotropic Effects of Statins

  2011cites this paper
• A Comparative Study on Atorvastatin Versus Methotrexate in Rheumatoid Arthritis in a Double Blind Placebo Control Trial.

  2011cites this paper
• Statins in Acute Coronary Syndrome Use of an Early Loading Dose

  2011influential citation
• Estatinas para el Síndrome Coronario Agudo Medicina basada en evidencia sobre la administración temprana con dosis de carga

  2011influential citation
• The effects of statins on hypoxia-induced proliferation and cell signalling pathways in pulmonary artery fibroblasts

  2010cites this paper
• Effect of Hydroxymethylglutaryl Coenzyme-A Reductase Inhibitors on the Long-Term Progression of Rheumatic Mitral Valve Disease

  2010cites this paper
• Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.

  2010cites this paper
• Perspectives of the non-statin hypolipidemic agents.

  2010cites this paper
• Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.

  2010cites this paper
• Hydroxymethylglutaryl coenzyme-a reductase inhibitors delay the progression of rheumatic aortic valve stenosis a long-term echocardiographic study.

  2009cites this paper
• American Diabetes Association Indications for Statins in Diabetes

  2009cites this paper
• Statins, ACE inhibitors and ARBs in cardiovascular disease.

  2009cites this paper
• Thrombopoietin limits IL-6 release but fails to attenuate liver injury in two hepatic stress models

  2009cites this paper
• Nasal High Flow

  2009cites this paper
• Biotechnological production and applications of statins

  2009influential citation
• Echocardiographic Study Progression of Rheumatic Aortic Valve Stenosis: A Long-Term Hydroxymethylglutaryl Coenzyme-A Reductase Inhibitors Delay the

  2009cites this paper
• Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension.

  2008cites this paper
• Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.

  2008cites this paper
• Pleiotropic effects: Should statins be considered an essential component in the treatment of dyslipidemia?

  2008cites this paper
• Emerging amyloid beta (Ab) peptide modulators for the treatment of Alzheimer's disease (AD)

  2008cites this paper
• Statins and stroke.

  2008cites this paper
• Acute protective effects of different doses of simvastatin in the rat model of renal ischemia-reperfusion injury.

  2008cites this paper
• On statin treatment to prevent sepsis in dialysis patients.

  2007cites this paper
• Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review

  2007cites this paper
• Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.

  2007cites this paper
• Following the mevalonate pathway to bone heal alley

  2007cites this paper